# A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

> **NCT02552953** · PHASE1 · COMPLETED · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** CYC065

## Key facts

- **NCT ID:** NCT02552953
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-28
- **Primary completion:** 2022-10-04
- **Final completion:** 2023-08-25
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02552953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02552953, "A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02552953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*